New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
10:16 EDTRIMM, RDS.A, MYGN, SJM, CNK, INFY, EIX, QLGC, KNXA, HMA, CF, DVA, TEVA, OXY, JNS, ELX, RATEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Hold from Buy at Canaccord... Bankrate (RATE) downgraded to Sector Perform from Outperform at RBC Capital... CF Industries (CF) downgraded to Neutral from Overweight at Piper Jaffray... Cinemark (CNK) downgraded to Neutral from Overweight at JPMorgan... Emulex (ELX) downgraded to Sell from Neutral at Goldman... Health Management (HMA) downgraded to Sell from Fair Value at CRT Capital... J.M. Smucker (SJM) downgraded to Equal Weight from Overweight at Stephens... Janus Capital (JNS) downgraded to Sell from Neutral at Goldman... Kenexa (KNXA) downgraded to Market Perform from Outperform at JMP Securities... Myriad Genetics (MYGN) downgraded to Neutral from Buy at Mizuho... Occidental Petroleum (OXY) downgraded to Hold from Buy at Deutsche Bank... QLogic (QLGC) downgraded to Sell from Neutral at Goldman... Regal Entertainment (RGC) downgraded to Neutral from Overweight at JPMorgan... Royal Dutch Shell (RDS.A) downgraded to Hold from Buy at Deutsche Bank... Teva (TEVA) downgraded to Neutral from Buy at UBS... Edison International (EIX) downgraded to Market Perform from Outperform at Bernstein... Research in Motion (RIMM) downgraded to Sell from Hold at Canaccord... DreamWorks (DWA) downgraded to Sell from Hold at Stifel Nicolaus... Infosys (INFY) downgraded to Neutral from Outperform at Cowen.
News For A;TEVA;EIX;RIMM;DVA;INFY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
08:30 EDTTEVATeva launches generic Aggrenox capsules in the U.S.
Teva announced the launch of generic Aggrenox capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot. Aggrenox capsules had annual sales of approximately $457M in the United States, according to IMS data as of April.
08:11 EDTTEVATeva, Xenon provide update on TV-45070 Phase 2b study in OA pain
Subscribe for More Information
08:04 EDTTEVATeva, Xenon Pharmaceuticals provide update on TV-45070 Phase 2b study
Subscribe for More Information
08:01 EDTTEVATeva CEO: Pharma industry undergoing “very big shakeup,” Globes reports
Subscribe for More Information
June 30, 2015
10:01 EDTEIXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:27 EDTTEVAPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
June 29, 2015
17:04 EDTEIXEdison International initiated with a Neutral at Mizuho
Subscribe for More Information
June 26, 2015
10:38 EDTTEVACourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
June 25, 2015
13:59 EDTTEVATeva initiated with a Hold at HSBC
Subscribe for More Information
12:52 EDTTEVAEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
08:20 EDTEIXEdison International weakness overdone, says SunTrust
Subscribe for More Information
08:05 EDTTEVATeva, Active Biotech say patient enrollment finalized for CONCERTO trial
Subscribe for More Information
June 24, 2015
15:31 EDTEIXEdison International puts active as shares pullback
Subscribe for More Information
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
06:32 EDTDVADaVita discloses it received subpoena from Inspector General
In a regulatory filing, DaVita disclosed that the company recently received a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the company’s and its subsidiaries’ provision of services to Medicare Advantage plans and Medicare Advantage organizations and related patient diagnosis coding and risk adjustment submissions and payments. DaVita believes that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. In the event that the company were to incur liability related to this matter, the company would pursue an indemnification claim against the sellers secured by the escrow. We can make no assurances that the indemnification and escrow would cover the full amount of our potential losses related to this matter. The company is cooperating with the government and will gather and produce the requested information.
06:30 EDTDVADaVita discloses Robert Margolis not re-nominated as co-chairman of company
Subscribe for More Information
June 23, 2015
14:16 EDTTEVABMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
08:49 EDTTEVAMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information
June 21, 2015
19:53 EDTTEVAMylan CEO says Teva's 4.61% stake may be 'illegal,' Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use